HOME >> BIOLOGY >> NEWS
Accentia Biopharmaceuticals announces option agreement with Mayo

(NASDAQ : ABPI) announced today that it has signed an option agreement with the Mayo Foundation for Medical Education and Research for the exclusive right to negotiate a license for a method of use for any and all antifungals other than amphotericin B applied intranasally for the treatment of chronic sinusitis, sometimes known as chronic rhinosinusitis. If unexercised, the option expires on December 6, 2006. Accentia has previously obtained a worldwide exclusive license for the method of use, utilizing the antifungal, amphotericin B, for this indication. Accentia is developing a unique formulation of amphotericin B for intranasal application for the treatment of chronic sinusitis under an Investigational New Drug Application (IND).

Chronic sinusitis affects an estimated 31 million Americans. The symptoms are three or more months of chronic nasal obstruction, nasal discharge, and periocular headaches or pressure sensation. The symptoms of chronic inflammation could include the growth of inflammatory polyps in the nose, and recurrent bouts of acute bacterial sinusitis. There is no approved pharmaceutical for the indication of chronic sinusitis. Many patients with severe disease resort to sinus surgery in an attempt to relieve nasal obstruction and improve sinus drainage. The Mayo Clinic researchers have identified a ubiquitous air-borne fungus in the mucus of the nose and sinuses that elicits an inflammatory response in susceptible patients. Published studies at the Mayo Clinic and elsewhere have demonstrated a significant improvement in signs and symptoms of chronic sinusitis in patients treated with intranasal amphotericin B.

"We are working diligently to develop the Mayo patented technology for the treatment of chronic sinusitis with intranasal amphotericin B," said Steve Arikian, MD, President and COO of Accentia's Product Development and Market Services. "We recognized that our impending clinical trials of amphotericin B for this indication, if
'"/>

Contact: Sherran Brewer
sbrewer@accentia.net
866-481-9020
SciWords
15-Dec-2005


Page: 1 2

Related biology news :

1. FDA grants Accentia Biopharmaceuticals...
2. AutovaxID-C introduced by Accentia Biopharmaceuticals
3. Accentia Biopharmaceuticals acquires exclusive license
4. Accentia Biopharmaceuticals, Inc. launches CRSFungal Profile
5. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
6. ESA announces 2007 award recipients
7. President Bush announces 2005 and 2006 Laureates of National Medals of Science and Technology
8. Conservation Leadership Program announces 2007 awardees
9. ACMG Foundation announces 2007-2008 Luminex/ACMGF award recipient
10. Revolutionary global environment fund announces $50M expansion
11. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2020)... Va. (PRWEB) , ... July 08, 2020 , ... ... Latest on Cell and Gene Therapy Regulation, An FDAnews Webinar, Wednesday, July 22, ... need a comparability study, but what is the most effective way to complete ...
(Date:7/2/2020)... ... July 01, 2020 , ... ... 1a findings of Neihulizumab, a biologic for the treatment of steroid-refractory acute graft-versus-host ... by hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson Cancer Research Center, ...
(Date:7/1/2020)... ... July 01, 2020 , ... Cure Glioblastoma, ... glioblastoma—the most common and aggressive adult brain cancer—announced today the appointments of its ... are charged with supporting the organization’s initiatives and overall vision. , "Senior Fellows ...
Breaking Biology News(10 mins):
(Date:9/1/2020)... ... 01, 2020 , ... Slone Partners , a nationwide ... placement of Julianne Averill , CPA, as Chief Financial Officer at ... implementing key business strategies to accelerate Alveo’s growth as the company advances its ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... available for free its new white paper – Simulated Transport Methodologies. Regulatory ... today’s biologics licensing application (BLA). In response, Modality Solutions shares an explanation ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is now offering patients ... million stem cells total, patients may choose which extremities they would like treated. , ... (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained from a ...
(Date:7/31/2020)... ... ... eSource has long been touted as the solution to high data management and monitoring ... did not take off as quickly as people initially expected, and where eSource is ... data electronically for clinical trials and then repurposing it for downstream analysis, at a ...
Breaking Biology Technology:
Cached News: